- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03855631
Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders (Epi-KAB)
Starting from isolating primary cells from affected patients, an in vitro disease model system for KS will be developed. Using alternative strategies to obtain patient-derived mesenchymal stem cells, an integrative approach will be adopted for defining both the transcriptional and epigenetic regulatory networks perturbed upon the loss of function of KMT2D. Combining the self-renewal potential of mesenchymal stem cells (MSCs) with CRISPR/Cas9 technology, an epigenome editing approach as therapeutic strategy to rescue the activity of MLL4 will be developed.
A step forward is expected towards the understanding of those the molecular mechanisms governing the aetiology of Kabuki Syndrome (KS) and that the proposed in vitro disease model will provide to the scientific community an experimental system to study the KS. Importantly, the aim is to define the molecular bases of KS and to develop a therapeutic strategy that could ameliorate some of the abnormalities associated with KS.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Main and secondary objectives :
The main objective is to study the pathological role of ML mutations in KS to facilitate the identification and characterization of therapeutic strategies to improve the symptoms of patients with KS. Due to the lack of treatment in the KS, the aim is to develop a model of this disease from fibroblasts from patients and reprogram them into mesenchymal stem cells. This approach will generate a KS-specific stem cell bio-bank, allowing the identification of common disturbances caused by the loss of function (LoF) of KMT2D. The impact of the KMT2D LoF on transcription but also the epigenetic mechanisms activated during MSC differentiation will be described. Finally, the therapeutic potential of an epigenome "editing" approach to increase the expression of the wild KMT2D allele to restore the functional activity of MLL4 in treated MSCs will be evaluated.
The secondary objective is to evaluate the ability to return to normal after CRISPR/Case9 gene therapy treatment on patients' cells
Methodology (design study, population, description of groups (if applicable), inclusion criteria, non-inclusion, main and secondary judgment criteria, number of subjects to be included, statistical analysis...) :
Starting from primary cells isolated from affected patients, an in vitro model of the disease will be developed. An integrative but alternative strategy approach to obtain mesenchymal stem cells derived from patients to define normal and abnormal transcription and epigenetic circuits during KMT2D LoF will be adopted. By combining the autonomous renewal potential of MSCs with CRISPR/Cas9 technology, an approach to "editing" the epigenome for therapeutic purposes to restore MLL4 activity will be developed.
This project will represent a step forward in understanding the molecular mechanisms responsible for KS. The in vitro model will provide the scientific community with an experimental system to study KS. Finally, the aim is to define the molecular basis of KS and develop a therapeutic strategy to improve certain symptoms in patients with KS.
Process (number of visits, duration of inclusions, duration of follow-up):
8 people will be included: 4 patients with Kabuki syndrome authenticated by the molecular genetics study of the KMT2D gene.
4 parents of the same sex as the patient
Feasibility :
In the clinical genetics department of the Montpellier University Hospital, more than 40 patients with Kabuki syndrome are followed.
Impacts / prospects :
The identification of the consequences of mutations in the KMT2D gene on epigenetic mark changes and cellular structural changes as well as the attempt at gene correction by CRISPR/Cas9 will provide a better understanding of the disease (and the genes that are deregulated by post-KMT2D epigenetic changes) and will also open a promising path for gene therapy by CRISPR/Cas9 method.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Herault
-
Montpellier, Herault, France, 34295
- Arnaud de villeneuve Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- For the patient = to have a Kabuki syndrome authenticated by molecular genetics (proof of mutation in the KMT2D gene)
- For parents = having the same sex as your child
- To be affiliated to a French social security system
- Authorize the participation of the study
Exclusion Criteria:
- Not be affiliated to a social security scheme (CMU is included)
- Existence of a significant coagulation ruble (especially thrombocytopenic purpura in Kabuki patients with platelet counts < 20,000 Units).
- Genetic skin disease responsible for poor healing
- Refusal to participate in the child's and/or parent's study
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Kabuki syndrome/ unaffected parents
Intervention on primary cultured cells from 4 patients with KS and sex match parents
|
The intervention includes primary cultured cells, reprograming them into mesenchymal stem cells and CRISPR/Case9 gene therapy treatment on patients' cells
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
success rate of fibroblasts culture
Time Frame: one year maximum after inclusion
|
The aim is to establish a model of KS disease from fibroblasts from patients
|
one year maximum after inclusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
success rate of turning fibroblasts into mesenchymal stem cells
Time Frame: one year maximum after inclusion
|
The aim is to determine the success rate of turning fibroblasts into mesenchymal stem cells
|
one year maximum after inclusion
|
success rate of CRISPR/Case9 gene therapy treatment on patients' cells
Time Frame: one year maximum after inclusion
|
The aim is to evaluate the ability to return to normal after CRISPR/Case9 gene therapy treatment on patients' cells
|
one year maximum after inclusion
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Alessio Zippo, PhD, Center of Integrative Biology
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RECHMPL18_0242
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kabuki Syndrome 1
-
University Hospital, MontpellierCompleted
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Hugo W. Moser Research Institute at Kennedy Krieger...Active, not recruiting
-
Juan PascualNational Institute of Neurological Disorders and Stroke (NINDS)CompletedGlucose Metabolism Disorders | Epilepsy | Glucose Transporter Type 1 Deficiency Syndrome | Glut1 Deficiency Syndrome 1, Autosomal Recessive | Glucose Transporter Protein Type 1 Deficiency Syndrome | Glucose Transport Defect | GLUT1DS1United States
-
University of Texas Southwestern Medical CenterRecruitingGlucose Metabolism Disorders | Epilepsy | Glucose Transporter Type 1 Deficiency Syndrome | Glut1 Deficiency Syndrome 1 | Glut1 Deficiency Syndrome 1, Autosomal Recessive | Glucose Transporter Protein Type 1 Deficiency Syndrome | Glucose Transport DefectUnited States
-
University of Texas Southwestern Medical CenterNational Institute of Neurological Disorders and Stroke (NINDS)Active, not recruitingGlucose Metabolism Disorders | Epilepsy | Glucose Transporter Type 1 Deficiency Syndrome | Glut1 Deficiency Syndrome 1, Autosomal Recessive | Glucose Transporter Protein Type 1 Deficiency Syndrome | Glucose Transport Defect | GLUT1DS1United States
-
University of Texas Southwestern Medical CenterRecruitingGlucose Transporter Type 1 Deficiency Syndrome | GLUT1 Deficiency Syndrome | Glucose Transporter type1 (GLUT-1) Deficiency | GLUT-1 Deficiency SyndromeUnited States
-
Jerry Vockley, MD, PhDUltragenyx Pharmaceutical IncNo longer availableGlucose Transporter 1 Deficiency SyndromeUnited States
-
Juan PascualNo longer availableGlucose Transporter Type 1 Deficiency Syndrome | Glut1 Deficiency SyndromeUnited States
-
Juan PascualCompletedGlucose Transporter Type 1 Deficiency Syndrome | GLUT1 Deficiency SyndromeUnited States
Clinical Trials on Intervention on primary cultured cells
-
Centre Hospitalier National d'Ophtalmologie des...Etablissement Français du SangCompleted
-
H. Lee Moffitt Cancer Center and Research InstituteCompletedGraft Versus Host DiseaseUnited States
-
National Taiwan University HospitalTerminatedUnilateral Limbal Stem Cell InsufficiencyTaiwan
-
Universidad Autonoma de MadridCompletedAvascular Necrosis of the Femoral HeadItaly, France, Germany, Spain
-
Aderans Research InstituteCompletedAndrogenetic Alopecia | Male Pattern Baldness | Female Pattern BaldnessUnited States
-
Aderans Research InstituteCompletedAndrogenetic Alopecia | Male Pattern Baldness | Female Pattern BaldnessUnited States
-
Aderans Research InstituteCompletedAndrogenetic Alopecia | Male Pattern Baldness | Female Pattern BaldnessUnited States
-
Royan InstituteSmall Business Developing Center; Labafi Nejad Eye Research CenterCompletedLimbal Stem Cell DeficiencyIran, Islamic Republic of
-
Maastricht University Medical CenterAdelante, Centre of Expertise in Rehabilitation and Audiology; The Province... and other collaboratorsCompletedLow Back Pain | Musculoskeletal Pain | Chronic PainNetherlands
-
Aderans Research InstituteCompletedAndrogenetic Alopecia | Male Pattern Baldness | Female Pattern BaldnessUnited States